{
    "nctId": "NCT00110136",
    "briefTitle": "St. John's Wort in Relieving Hot Flashes in Postmenopausal Women With Non-Metastatic Breast Cancer",
    "officialTitle": "A Phase II Study of St. John's Wort for the Treatment of Hot Flashes in Women With a History of Breast Cancer",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer, Hot Flashes",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 9,
    "primaryOutcomeMeasure": "Effect of St. John's Wort on Hot Flash Frequency as Recorded in a Daily Hot Flash Diary From Baseline to 4 Weeks",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Diagnosis of 1 of the following:\n\n  * Noninvasive ductal carcinoma in situ\n  * Localized breast cancer\n\n    * Stage 0-IIIB disease\n  * Locally recurrent breast cancer that is post-treatment AND disease-free for \u2265 2 years\n* Experiencing \u2265 3 hot flashes per day (\u2265 21 per week), defined by sweating, flushing, sensation of warmth, night sweats, and/or rapid heart beat of sufficient severity that the patient desires therapeutic intervention\n* Normal mammogram within the past 10 months\n* Hormone receptor status:\n\n  * Not specified\n\nINCLUSION CRITERIA:\n\nAge\n\n* 18 and over\n\nSex\n\n* Female\n\nMenopausal status\n\n* Post-menopausal (i.e., no menstrual periods \u2265 12 months or surgical menopause)\n\nPerformance status\n\n* ECOG 0-2\n\nLife expectancy\n\n* Not specified\n\nHematopoietic\n\n* Not specified\n\nHepatic\n\n* Bilirubin \\< 2 mg/dL\n* SGOT \u2264 2 times normal\n\nRenal\n\n* Not specified\n\nEXCLUSION CRITERIA:\n\n* Not pregnant or nursing\n* Fertile patients must use effective contraception\n* No history of intolerance to St. John's wort\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy\n\n* Not specified\n\nChemotherapy\n\n* No concurrent cytotoxic chemotherapy\n\nEndocrine therapy\n\n* No concurrent selective estrogen-receptor modulators or aromatase inhibitors (e.g., anastrozole, letrozole, or exemestane) allowed\n\n  * Concurrent tamoxifen allowed\n* No concurrent estrogen, progestational agents, or androgens for the alleviation of hot flashes\n* No concurrent corticosteroids\n\nRadiotherapy\n\n* Not specified\n\nSurgery\n\n* Not specified\n\nOther\n\n* More than 14 days since prior Hypericum perforatum (St. John's wort), monoamine oxidase inhibitors, selective serotonin reuptake inhibitors (e.g., sertraline, paroxetine, or fluoxetine) or selective norepinephrine reuptake inhibitors (e.g., venlafaxine)\n* No concurrent use of any of the following:\n\n  * Antidepressants\n  * Theophylline\n  * Warfarin, unless for central line prophylaxis\n  * Protease inhibitors for AIDS\n  * Digoxin\n  * Cyclosporine\n  * Benzodiazepines (e.g., diazepam or alprazolam)\n  * Calcium-channel blockers (e.g., diltiazem or nifedipine)\n  * Coenzyme A reductase inhibitors for serum cholesterol reduction\n  * Macrolide antibiotics (e.g., azithromycin, erythromycin, or clarithromycin)\n  * Griseofulvin\n  * Phenobarbital\n  * Phenytoin\n  * Rifampin\n  * Rifabutin\n  * Grapefruit juice\n  * Other naturopathic or herbal products\n  * Ketoconazole\n  * Fluconazole\n  * Itraconazole\n  * Rifabutin\n* No other concurrent medications for the alleviation of hot flashes (e.g., clonidine or bellamine)",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}